Bionoid Pharma Valuation
| BINP Stock | USD 0.20 0.05 33.33% |
Bionoid Pharma seems to be overvalued based on Macroaxis valuation methodology. Our model approximates the value of Bionoid Pharma from analyzing the firm fundamentals such as Return On Asset of -1.64, price to sales of 540.76 X, and Current Valuation of 3.81 M as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Bionoid Pharma's price fluctuation is out of control at this time. Calculation of the real value of Bionoid Pharma is based on 3 months time horizon. Increasing Bionoid Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Bionoid Pharma's intrinsic value may or may not be the same as its current market price of 0.20, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.2 | Real 0.17 | Hype 0.2 | Naive 0.25 |
The intrinsic value of Bionoid Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Bionoid Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Bionoid Pharma helps investors to forecast how Bionoid pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Bionoid Pharma more accurately as focusing exclusively on Bionoid Pharma's fundamentals will not take into account other important factors: Bionoid Pharma Total Value Analysis
Bionoid Pharma is currently estimated to have valuation of 3.81 M with market capitalization of 42.28 M, debt of 64.5 K, and cash on hands of 127. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Bionoid Pharma fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
3.81 M | 42.28 M | 64.5 K | 127 |
Bionoid Pharma Investor Information
The company recorded a loss per share of 46.27. Bionoid Pharma had not issued any dividends in recent years. The entity had 1:2500 split on the 25th of February 2020. Based on the key measurements obtained from Bionoid Pharma's financial statements, Bionoid Pharma is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Bionoid Pharma Asset Utilization
One of the ways to look at asset utilization of Bionoid is to check how much profit was generated for every dollar of assets it reports. Bionoid Pharma shows a negative utilization of assets of -1.64 percent, losing $0.0164 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Bionoid Pharma shows how discouraging it operates for each dollar spent on its assets.Bionoid Pharma Profitability Analysis
The company reported the previous year's revenue of 92.26 K. Net Loss for the year was (1.62 M) with profit before overhead, payroll, taxes, and interest of 47.48 K.About Bionoid Pharma Valuation
The pink sheet valuation mechanism determines Bionoid Pharma's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Bionoid Pharma based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Bionoid Pharma. We calculate exposure to Bionoid Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Bionoid Pharma's related companies.Bionoid Pharma Inc. engages in the hemp cultivation business. Bionoid Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 5 people.
8 Steps to conduct Bionoid Pharma's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Bionoid Pharma's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Bionoid Pharma's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Bionoid Pharma's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Bionoid Pharma's revenue streams: Identify Bionoid Pharma's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Bionoid Pharma's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Bionoid Pharma's growth potential: Evaluate Bionoid Pharma's management, business model, and growth potential.
- Determine Bionoid Pharma's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Bionoid Pharma's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Bionoid Pharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as Bionoid Pharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Retained Earnings | -20.2 M |
Additional Tools for Bionoid Pink Sheet Analysis
When running Bionoid Pharma's price analysis, check to measure Bionoid Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bionoid Pharma is operating at the current time. Most of Bionoid Pharma's value examination focuses on studying past and present price action to predict the probability of Bionoid Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bionoid Pharma's price. Additionally, you may evaluate how the addition of Bionoid Pharma to your portfolios can decrease your overall portfolio volatility.